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ABSTRACT
The therapeutic responses of many solid tumours to chemo- and radio-therapies 
are far from fully effective but therapies targeting malignancy-related cellular changes 
show promise for further control. In head and neck squamous cell carcinoma, the 
epidermal growth factor receptor (EGFR) is commonly overexpressed and investigation 
of agents that block this receptor indicate a limited response when used alone but 
an ability to enhance the actions of other drugs. The hierarchical stem cell patterns 
present in tumours generate cellular heterogeneity and this is further complicated by 
cancer stem cells (CSC) shifting between epithelial (Epi-CSC) and mesenchymal (EMT-
CSC) states. To clarify how such heterogeneity influences responses to EGFR blocking, 
we examined the effects of Cetuximab and Erlotinib on the cell sub-populations in 
HNSCC cell lines. These agents reduced cell proliferation for all subpopulations but 
induced little cell death. They did however induce large shifts of cells between the 
EMT-CSC, Epi-CSC and differentiating cell compartments. Loss of EMT-CSCs reduced 
cell motility and is expected to reduce invasion and metastasis. EGFR blocking also 
induced shifts of Epi-CSCs into the differentiating cell compartment which typically 
has greater sensitivity to chemo/radiation, an effect expected to enhance the overall 
response of tumour cell populations to adjunctive therapies.
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INTRODUCTION
Head and neck cancers are among the 10 most 
common cancers worldwide and the great majority of 
these cancers are squamous cell carcinomas and associated 
with severe mortality [1–3]. Currently the usual treatment 
for HNSCC patients remains surgery in combination 
with radiotherapy and this is further combined with 
chemotherapy for more advanced disease and for recurrent 
and metastatic tumours [4–6]. Despite therapeutic 
advances during the last decade, the 5-year-survival rate 
for HNSCC remains low with late diagnosis at advanced 
tumour stages typically associated with local and regional 
recurrences, and with development of lymph node and 
distant metastasis [7, 8]. The poor therapeutic responses 
of HNSCC have encouraged focused efforts towards 
development of molecular targeted therapies [7, 9, 10]. 
Overexpression of the epidermal growth factor 
receptor (EGFR) is a frequent molecular alteration in 
HNSCC and increased activity of the EGF pathway has 
been associated with resistance to treatment and poor 
clinical outcome [5, 11, 12]. The EGFR is a member of 
the HER tyrosine kinase receptor family and binding of 
specific ligands, such as epidermal growth factor (EGF) 
and transforming growth factor alpha (TGF-α), promotes 
homo- or hetero-dimerization of EGFR family members 
and activation of intracellular signaling pathways that 
control growth, differentiation, survival and invasion 
[13–15]. The EGFR is therapeutically targeted by agents 
such as Cetuximab and Erlotinib [6] but the modest effects 
observed on tumour control have been rather disappointing 
considering the importance of EGFR-initiated signaling 
pathways. Various mechanisms for primary and acquired 
resistance to Cetuximab have been suggested and include 
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constitutive activation of EGFR-mediating signaling 
molecules and activation of alternative ErbB2 and ErbB3 
pathways [16, 17].
There is now substantial evidence that HNSCC, 
like other solid tumours, consist of a heterogeneous 
population of cells. This results partly from the evolution 
of clonal heterogeneity [18] but is also due to persistence 
of a hierarchy of stem and differentiating cells similar to 
that present in normal tissues [19, 20]. Cancer stem cells 
(CSCs) are identified as a subpopulation of cells with the 
ability to self-renew indefinitely whilst also generating 
daughter cells that differentiate, usually aberrantly, and the 
self-renewal properties of CSCs are tested by their selective 
ability to initiate tumours in immune-deficient mice [21]. 
The CSC subpopulation not only drives tumour growth but 
is also responsible for the aggressiveness and therapeutic 
resistance of tumours [22]. CSCs in HNSCC were initially 
identified and isolated by their high levels of expression 
of the hyaluronan receptor CD44 [19, 23, 24] and several 
subsequent reports have described isolation of CSCs from 
HNSCC using either CD44 or various other markers [25]. 
CSCs also persist in malignant cell lines and can be identified 
by high levels of CD44 expression, by morphological 
characteristics, and by their clonogenicity [23]. 
Of particular interest, tumour invasion and metastasis 
have been linked to epithelial-mesenchymal transition 
(EMT), a process during which cells lose epithelial features 
of mutual attachment and gain mesenchymal features, 
including mobility [26–29]. It is proposed that EMT enables 
CSCs to invade surrounding local and distant tissues where 
the reverse process of mesenchymal-to-epithelial transition 
(MET) enables their return to the epithelial phenotype to 
generate metastatic growth [30]. Biddle and co-workers 
[31] demonstrated that the self-renewing CD44high CSC 
fraction of HNSCC contains as at least two distinct cellular 
phenotypes with marked differences in cell motility, 
morphology, proliferation, clonogenicity, and sphere 
forming abilities. Both cell fractions are tumour-initiating 
and both express high levels of CD44 but the CSCs with 
an epithelial phenotype express high levels of ESA whereas 
those that have undergone EMT have low or absent levels 
of ESA [31]. CSCs have the ability to switch between these 
phenotypes and, as a result, aggressive tumours consist 
of at least 3 cell types, epithelial CSCs, mesenchymal 
CSCs, and a differentiating non-stem cell fraction [31]. A 
comprehensive understanding of drug actions will therefore 
depend on information about the individual responses of 
each of these cell types. 
Apart from their EMT-mediated roles in invasion and 
metastasis, the therapeutic importance of CSCs lies in their 
greater ability to resist therapeutic killing in response to 
radio- and chemo-therapies [22, 32, 33]. Differential effects 
of CSC sub-fractions to the molecularly targeted therapies 
of agents such as Cetuximab and Erlotinib are therefore 
of interest [34]. We have now investigated the effects of 
blocking EGFR function on each of the phenotypically-
different cell sub-populations in HNSCC cell lines and find 
that EGFR inhibition leads to morphological and molecular 
changes, marked reductions in cell proliferation, but no 
marked induction of cell death. It leads to reduced CD44 
expression and a shift of CSCs into differentiation, a state 
in which they have enhanced therapeutic sensitivities. 
This action provides a form of “differentiation therapy” 
[35–37] and appears related to the greater effectiveness of 
EGFR inhibition when used as an adjunctive component of 
therapies. Both Cetuximab and Erlotininib also shift EMT-
CSCs back into the epithelial phenotype, a change that may 
tend to restrict local invasion and metastasis. 
RESULTS
Effects of Cetuximab and Erlotinib on cell 
proliferation and apoptosis in HNSCC cell lines.
Treatment levels were initially determined by 
treating CA1 and Luc4 cell lines for 3 days with drug 
concentrations of Cetuximab and Erlotinib ranging from 
0–500 µg/ml or 0–500 ng/ml respectively (Figure 1A, 1B). 
Based on these pilot data, Cetuximab at a dose of 100 µg/
ml, and Erlotinib at a dose of 500 ng/ml, were used for 
subsequent experiments. By day 3, both drugs induced 
marked morphological changes, including the formation 
of more compact cell colonies and loss of individual 
elongated EMT-like cells (Figure 1C). Cell cultures were 
examined to assess the extent to which the reduced cell 
numbers present after 3 days of treatment (Figure 1D) were 
related to reduced proliferation or to increased apoptosis. 
Cytometry after staining for Annexin V and DAPI showed 
low (2–4%) levels of apoptosis in untreated cells. The lack 
of significant increases in counts of Annexin V positive 
cells after treatment indicated no marked promotion of 
apoptotic cell death (Figure 1E). Effects of treatment in 
markedly reducing rates of cell cycling were indicated by 
significant decreases in IdU labeled cells (Figure 1F, 1G). 
Cetuximab and Erlotinib decrease the levels of 
CD44 expression of CA1 and Luc4 cells.
To further assess the effects of EGFR inhibitors, we 
examined whether there were differential changes in the 
cell line sub-fractions we have previously identified . Cells 
were stained for CD44 and ESA and fractionated by flow 
cytometry into CD44high/ESAlow (EMT-CSC), CD44high/
ESAhigh (EPI-CSC) and CD44low (NON-CSC) populations. 
For both cell lines, treatment significantly decreased the 
percentage of CD44high/ESAhigh cells and consistently 
increased the percentage of CD44low cells (Figure 1H, 1I). 
Following treatment CD44high/ESAlow fractions showed 
no statistically significant differences in mean CD44 or 
ESA expression levels, and the proportion of this fraction, 
expressed as a percentage of the total cells, also remained 
unchanged. 
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To determine whether the decreases in CD44 
expression indicated by flow cytometry were associated 
with functional decreases in stemness, treated cell lines 
were re-plated at low density to assess their colony-
forming abilities. Treated cells of both cell lines showed 
significant reductions in colony forming ability (Figure 2A 
and 2B) but no significant differences in their ability to 
form tumour spheres (Figure 2C).
Cetuximab and Erlotinib alter EGFR expression 
patterns
Differences in EGFR expression induced by 
Cetuximab and Erlotinib were evaluated by flow 
cytometry and western blotting. Plots of EGFR versus 
side-scatter indicated that the control populations of both 
cell lines had similar and substantial levels of total cell 
surface EGFR and that these levels increased following 
treatment (Figure 2D–2F). Control populations of both 
CA1 and Luc4 showed higher expression of EGFR on 
the CD44high/ESAhigh Epi-CSC subfraction than on either 
CD44high/ESAlow or CD44low cells and there was a trend 
for expression in all fractions to increase after treatment. 
Immunofluorescence showed cytoplasmic staining with 
higher than control levels of EGFR at the cell peripheries 
of the cohesive cell colonies formed following treatment 
(Figure 2G). Following treatment, Western blots indicated 
little difference in the overall levels of pEGFR or EGFR 
but showed reduced levels of the downstream target pERK 
indicated that both inhibitors functioned to interrupt the 
primary EGFR signaling pathway (Figure 2H).
Cetuximab and Erlotinib decrease the 
proliferation rates of all cell fractions and 
prevent G1/S progression
To evaluate proliferative effects of Cetuximab or 
Erlotinib treatment on the CD44high/ESAlow, CD44high/
ESAhigh and CD44low fractions, cells were sorted and re-
plated. Treatment resulted in a reduced accumulation of 
cells for each of the sorted fractions of both cell lines with 
levels of IdU incorporation significantly and similarly 
reduced for all sub-fractions (Figure 2I–2L). Counts of 
Annexin V positive cells indicated low levels of apoptosis 
in control specimens and treatment-induced changes in 
apoptosis were small and not significant for any of the 
3 cell sub-fractions (Figure 2M). Cyclin D1, which is 
required for progression of cells through the G1/S cell 
cycle phase, also showed significant decreases in all cell 
fractions with both treatments (Figure 2N). 
Cetuximab and Erlotinib increase cell 
differentiation
The observed treatment effects of loss of cells from 
the CD44high/ESAhigh cell fractions, reduction in colony 
forming assays, and an increased proportion of CD44low 
cells indicated a shift of cells from the Epi-CSCs stem 
cell compartment into differentiation. To assess other 
indicators of differentiation, we examined changes in 
cell size and in cytoplasmic-to-nuclear ratio as these 
are known to increase with differentiation. Following 
treatment, sorted cell fractions showed trends towards 
an increased cell size, mean cell area and cytoplasmic to 
nuclear ratio (Figure 3A–3C). Expression of the epithelial 
differentiation markers Calgranulin B and Involucrin 
was found to be lowest in the CD44high/ESAlow EMT 
cell fractions, and the highest in the CD44low fractions 
and significant increases in these markers for all cell 
fractions indicated that treatment resulted in shifts towards 
differentiation (Figure 3D, 3E).
Cetuximab and Erlotinib effects on the size of 
EMT cell fractions, rates of cell migration, and 
cisplatin responses
Control cultures showed populations of scattered 
cells with an EMT-like appearance and their loss after 
treatment suggesting a transition of EMT cells back 
to an epithelial-like phenotype. As little increase in 
ESA expression was detected by FACS, we examined 
FACS-isolated CD44high/ESAlow EMT fractions for other 
evidence of mesenchymal-epithelial transition (MET). 
QPCR (Figure 3F) and immunofluorescence staining cell 
indicated significant decreases in vimentin expression and 
increases in E-cadherin expression in treated populations 
(Figure 3F–3H). The loss of scattered e-cadherin negative/
vimentin positive cells seen in control cultures was again 
associated with cell clustering to form compact colonies.
A shift of EMT cells towards an epithelial 
phenotype was assessed in two other ways. When FACS-
isolated EMT-CSCs were plated and grown for 3 days, 
cells from control cultures maintained an EMT-like 
appearance whereas treated cultures began to transit into 
cell clusters with an epithelial appearance (Figure 4A, 
top). The contribution of EMT-CSCs to the compact 
colonies was apparent when EMT-CSCs were isolated 
from EGFP-labeled cultures and mixed and plated with 
unlabeled CD44high/ESAhigh EPI-CSCs. These cultures 
initially showed individual elongated EGFP-labeled cells 
that were distinct from the unlabeled epithelial colonies 
but by 72 hours after treatment clusters of EGFP-labeled 
cells were present within and around the epithelial 
colonies (Figure 4A, lower) indicating a morphological 
transition from EMT-CSCs into an epithelial state. 
Scratch assays showed marked changes in cell motility 
as a result of EGFR blocking. Scratches in control wells 
were essentially closed within 16 hours whereas after 
EGFR inhibition scratches remained open even at 24 hours 
(Figure 4B–4D). Cultures treated with Cisplatin were 
treated with Cetuximab or Erlotinib 3 days later to see 
whether EGFR blocking enhanced the effects of Cisplatin 
treatment. Both cell lines showed the enhanced effects on 
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Figure 1: Effects of Cetuximab and Erlotinib on cell proliferation and apoptosis in HNSCC cell lines. Percentage of 
total number of CA1 (A) and Luc4 (B) cells compared to controls after 3 days of treatment with Cetuximab and Erlotinib at various 
concentrations. (C) Cell morphology of CA1 and Luc4 after treatment with Cetuximab (100 µg/ml) and Erlotinib (500 ng/ml) for 3 days 
(Scale = 50μm). (D) Total number of CA1 and Luc4 after each day of treatment. (E) Analysis of Annexin V positive cells after 3 days 
treatment with either Cetuximab or Erlotinib. (F) Representative images of IdU positive cells (green) in CA1 and Luc4 after treatment with 
Cetuximab and Erlotinib (Scale = 25μm). (G) Quantification of the number of IdU positive cells. (H) FACS analysis of expression of CD44 
and ESA on CA1 and Luc4 cells after 3 days of treatment with Cetuximab or Erlotinib showing decrease of cells with CD44high/ESAhigh 
expression and increase the CD44high/ESAlow fraction. (I) Quantification of data depicted in H, showing the percentage of CD44high/ESAlow, 
CD44high/ESAhigh and CD44low fractions. For this and all subsequent figures; *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 2: Cetuximab and Erlotinib decrease clonogenicity, proliferation rates and EGFR expression. (A) Effects of 
treatment on colony forming ability. (B) Quantification of the number of colonies formed in CA1 and Luc4 cell lines. (C) Number of spheres 
formed after 3 days of treatment. (D) FACS plots of changes in the number of cells expressing cell-surface EGFR. (E, F) Comparisons 
of percentages of EGFR expressing cells in the two cell lines after treatment. (G) Altered patterns of EGFR staining after treatment. (H) 
Western blots showing protein levels for EGFR, pEGFR, and pERK. Altered patterns of cell proliferation (I–K), accumulation (L) and 
apoptosis (M) of cell sub-fractions following treatment. (N) Levels of Cyclin D1 were reduced in all sub-fractions. 
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Figure 3: Cetuximab and Erlotinib induce cellular differentiation. (A) Mean cell size of CD44high/ESAlow, CD44high/ESAhigh 
and CD44low fractions in CA1 and Luc4 cell lines after treatment. Representative graphs showing (B) increased size and (C) increased 
cytoplasmic/nuclear ratio of CD44high/ESAlow cells. In control cultures, expression of the differentiation markers Calgranulin B and 
Involucrin is normally lowest in CD44high/ESAlow sub-population (D) but is increased in all fractions (E) after treatment. (F) qPCR indicated 
reduced Vimentin and increased E-cadherin expression of EMT fractions after treatment. (G) Control cultures show some cohesive 
colonies staining for E-cadherin (green) surrounded by scattered DAPI-positive E-cadherin negative cells. After treatment with Cetuximab 
or Erlotinib scattered cells were lost and nearly all cells were E-cadherin positive. (H) Control cultures show numerous scattered vimentin-
positive (green) cells which, after treatment are reduced in number and tend to cluster into and around epithelial-like colonies (Scale for G 
and H = 25 μm) Inserts show colonies at higher magnification.
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the reduction in cell number when the drugs were used in 
combination (Figure 4E).
DISCUSSION 
Activation of the EGFR has widespread effects on 
cell proliferation, survival, invasion, DNA repair and drug 
resistance. This receptor is frequently overexpressed in 
HNSCC and has been extensively studied as a molecular 
target [38]. However, blocking EGFR signaling has 
provided less therapeutic benefit than initially anticipated 
[39] and this may be largely related to the cellular 
heterogeneity of tumours and, particularly, to the presence 
of sub-populations of CSCs and differentiating cells [40]. 
There is now considerable evidence that elimination 
of CSCs is required for successful therapy [26, 41] but 
it has also been found that CSCs generally have greater 
resistance to therapeutic killing by either radiation or 
chemotherapy [32, 42]. Therapeutic manipulation of CSCs 
is further complicated by their presence as heterogeneous 
populations of epithelial and mesenchymal phenotypes 
that differ in their therapeutic responses to individual 
therapies and are able to switch from one phenotype 
to the other [31, 40]. Information about the particular 
specificities of individual drugs for each type of cell 
may therefore be helpful in developing combinations 
of drugs that provide effective actions upon the total 
tumour population, potentially also at lower therapeutic 
concentrations. 
CD44 has been widely used as a general marker 
for CSC identification [23, 25] and has functions related 
to stem cell maintenance. For example, CD44 knockout 
mice show reduced epidermal differentiation [43] and 
CD44 down-regulation in tumour cells is associated 
with stem cell loss whereas over-expression of CD44 
drives tumour progression and promotes CSC properties 
[44–46]. EGFR activation increases CD44 expression, 
blocking EGFR tyrosine kinase domains reduces both 
stem cell maintenance and EMT, and loss of CD44 down-
regulates both total and phosphorylated EGFR [46, 47]. 
Taken together, these findings support the concept that 
drugs blocking EGFR signalling are likely to affect 
CSC maintenance, either directly or indirectly, and that 
information about differential effects of drugs on stem cell 
fractions is of therapeutic interest.
Cetuximab and Erlotinib interrupt EGFR signalling 
by different mechanisms but both strongly inhibited 
cell proliferation and produced distinct and similar 
morphological changes. Flow cytometry analysis indicated 
interesting drug effects on the CSC and non-CSC 
subpopulations in terms of shifts of cells between these sub-
fractions. The proportion of cells in CD44high/ESAhigh Epi-
CSC fractions was markedly reduced and the proportion 
of cells in CD44low fractions was correspondingly raised. 
The rates of cell proliferation and apoptosis for these 
subpopulations were not differentially affected by treatment 
with either drug. Therefore, the reduction in CD44high/
ESAhigh Epi-CSCs was attributed to their enhanced transit 
into the differentiating CD44low population. We have 
previously shown that clonogenic ability, assessed as the 
formation of adherent colonies, is primarily a property of 
Epi-CSCs [31] and the markedly reduced colony-forming 
efficiency of treated cells supports the concept of loss of 
Epi-CSCs by differentiation. Further evidence for this shift 
was found in the increased size of cells in this fraction and 
their increased expression of the Involucrin and Calgranulin 
B differentiation markers. 
Treated cultures showed a striking disappearance 
of the numerous scattered cells in control cultures that 
have an EMT-like appearance. Given this apparent 
loss of EMT cells by morphological criteria, it was 
surprising that EGFR inhibition induced no statistically 
significant differences in the number of cells expressing 
the CD44high/ESAlow cell surface phenotype, typically 
used as an identifier of EMT-CSCs in FACS assay 
[48]. Nor was there a change in sphere forming ability. 
Sphere formation has been used to assess the size of 
“functional” EMT-CSC fractions [31] and the Luc4 line, 
which has a larger fraction of CD44high/ESAlow EMT-
CSCs than the CA1 cell line, accordingly showed more 
sphere formation. However, although drug treatment 
did not induce consistent changes in sphere formation, 
the decreased Vimentin and increased E-cadherin levels 
found for sorted CD44high/ESAlow fractions indicated that 
some degree of transition of EMT-CSCs towards MET had 
occurred. This was also demonstrated by the treatment-
induced shifts of EGFP-labelled EMT cells into epithelial 
colonies. The treatment-induced EMT changes found 
therefore differed depending on the assays employed. 
However, ascribing a simple binary transition to epithelial 
and mesenchymal cells undergoing EMT/MET processes 
is perhaps over simplistic [11]. Stable hybrid epithelial/
mesenchymal phenotypes that co-express both epithelial 
and mesenchymal markers are described [31, 49–51] 
and the EMT-CSC subpopulation itself appears to be 
heterogeneous with expression of markers such as 
Aldehyde dehydrogenase 1 marking cells that retain 
lineage plasticity [31]. The lack of re-expression of ESA 
and shifts in sphere formation after EGFR blocking may 
represent partial transition within a hybrid epithelial/EMT 
phenotype. Alternatively, a 3-day period of treatment may 
be insufficient for the full transition of all properties.
The presence of cells expressing mesenchymal 
markers has previously been reported in breast, prostate 
and other carcinoma cell lines [11, 52, 53]. In HNSCC 
cell lines, EMT generates cells with a CD44high/ESAlow 
phenotype that are plastic, able to revert to the epithelial 
phenotype, and relatively resistant to radiation and various 
chemotherapeutic agents [11, 32, 48]. Mesenchymal 
cells in HNSCC have been variously identified by a 
CD44high/EGFRlow cell surface expression pattern [34], by 
a Vimentinhigh/E-cadherinlow staining pattern [54] and by 
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a CD44high/Aldhhigh staining pattern [55]. Mesenchymal 
cells are also found in epidermoid and oesophageal 
carcinoma cell lines [56] and it appears that EMT and 
MET cell transitions are a common feature of carcinomas 
[37]. An interesting interpretation of the EMT process is 
that it “generates cells with the properties of stem cells” 
[29, 57], a conclusion based mainly on the EMT-induced 
shift from a CD44high/CD24high to a CD44high/CD24low 
phenotype in mammary cell lines [57]). Although the latter 
corresponds to the phenotype of tumour initiating stem cells 
in breast cancer [58], other evidence shows that the shift 
of phenotypic properties induced by EMT occurs within 
the stem cell compartment itself, i.e. between CD44high/
CD24high Epi-CSCs and CD44high/CD24low EMT-CSCs [31, 
48]. As both Epi-CSCs and EMT-CSCs are self-renewing 
and capable of initiating and maintaining tumours, both cell 
types need to be eliminated for successful therapy [41, 59]. 
In response to environmental stimuli, Epi-CSCs 
transit into self-renewing CD44high/ESAlow EMT cells and 
can also revert back to the Epi-CSC phenotype by MET. 
For a given cell line, balanced rates of the EMT and MET 
transitions result in a relatively stable size of the EMT-
CSC fraction. Typically the rate of these transitions is slow 
taking, for example, 3 weeks for levels of EMT cells to 
be greatly increased by hypoxia or by TGFβ, and taking a 
similar time after withdrawal of stimuli for EMT cells to 
return to baseline levels [34, 60]. EGFR blocking greatly 
increased the rate of MET and within 3 days there was 
loss of cells with an EMT-like appearance and transition 
of labeled EMT-CSCs back into epithelial colonies. The 
expected effect of a rapid shift of cells out of the EMT 
fraction is to reduce the invasive and metastatic potential 
of the tumour population. 
Many reports indicate that the clinical response rate 
for patients with advanced HNSCC is low when treated with 
Cetuximab alone, but survival and loco-regional control 
are improved when patients are treated with Cetuximab in 
combination with radiotherapy, platinum-based therapy or 
fluorouracil [5, 12, 51, 61]. Similarly, patients with recurrent 
or metastatic HNSCC show only a 4.3% response rate to 
Erlotinib as a monotherapy [62], but have a response rate of 
70% for Erlotinib combined with cisplatin or radiotherapy 
[63, 64]. The present findings of flux between epithelial 
compartments, each having differing drug responses, may 
help to explain these observations. EGF has roles in both 
in initiating EMT and inhibiting epithelial differentiation 
[65, 66] and the present cytometric analyses of CD44 and 
ESA expression allow identification of shifts between 
Epi-CSCs, EMT-CSCs and differentiating cells [31, 32]. 
Figure 4F is a diagrammatic representation of the altered 
behaviour of these cell populations observed in response 
to EGFR blocking. The continuous transit of cells from the 
self-renewing Epi-CSCs compartment into CD44low/ESAhigh 
differentiating cells is enhanced by treatment. The increased 
differentiation of EPI-CSCs, indicated by the increased size 
of CD44low fractions, decreases the self-renewal of tumour 
cells and corresponds to a form of “differentiation therapy” 
[35, 37]. The greater therapeutic sensitivity of the CD44low/
ESAhigh cells is likely further to potentiate cell loss in the 
presence of other therapeutic agents and the combination 
of EGFR blocking with cisplatin produced such an effect 
in vitro.
Design of synergistic therapy regimes may 
enable elimination of CSCs and effective monitoring 
strategies allowing development of such combinations 
is imperative [11]. The primary aim of this study was to 
develop methods capable of assessing differential effects 
of EGFR blocking agents on recently identified CSC 
subpopulations. Murine transplantation models for studies 
of CSCs are typically restricted to examination only of 
patterns of tumour initiation, growth and histological 
features. Consequently, such in vivo models have only 
limited ability to directly image or identify the therapeutic 
responses of individual cell subtypes. The present results 
show that in vitro assays allow direct imaging and 
analysis of individual cell fractions and can therefore 
accurately detect therapy-relevant shifts in subpopulation 
compositions. As in vitro studies are adaptable to high 
throughput assays they can also be used to identify 
differential changes in CSC subpopulations under a wide 
range of therapeutic conditions. Such assessment of 
existing and newly-developed drugs may allow rational 
development of multiagent combinations able to provide 
overall control of each of the differing plastic CSC 
subpopulations that generate tumour growth, spread and 
therapy resistance. 
MATERIALS AND METHODS
Cell lines, growth conditions and exposure to 
drugs
The CA1 and Luc4 cell lines, previously isolated from 
oral squamous cell carcinoma were cultivated as previously 
described [31, 60] in an epithetial growth medium containing 
EGF (10 ng/ml) and 10% FBS with 5% CO2 at 37°. Cells 
were plated in triplicate into 96-well plates at 1 × 103 cells 
per well, cultured overnight and then exposed to Cetuximab 
(Erbitux, Merck KGaA, Darmstadt, Germany) or Erlotinib 
(Erlotinib HCL. OSI-744 Cat No. S1023, Selleckchem). Cells 
were fixed in 4% paraformaldehyde for 15 min, washed in 
PBS, permeabilized with 0.1% Triton-X for 20 min, and then 
incubated with Cell Mask Deep Red at a 1:50,000 dilution 
(Life Technologies) and 1 µg/ml DAPI (Sigma) before image 
acquisition and analysis. To separately assess drug effects on 
Epi-EMT and EMT-CSC populations, cells were sorted on 
the basis of CD44 and ESA staining for investigation by the 
methods described below.
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Colony and sphere formation assays
To test their clonogenic abilities, cells were 
trypsinized after 3 days of treatment and 1 × 102 cells in 
2 ml of medium added to each well of 6 well plates. After 14 
days of growth, cells were fixed in 4% paraformaldehyde, 
stained with crystal violet (0.04% in 1% ethanol) and 
colonies measuring at least 2mm in diameter were counted 
visually. To assess growth in suspension as tumour spheres, 
24 well plates were coated with 12 mg/ml PolyHEMA 
(2-hydroxyethyl methacrylate, Sigma) in 95% ethanol to 
prevent attachment, and then seeded 1 × 103 treated cells/
well in 0.5 ml medium containing 1% methylcellulose. 
After two weeks, the number of tumour spheres larger than 
300 μM were counted. 
Flow cytometry
For fluorescent activated cell sorting (FACS), 
cells were detached from cultures using trypsin-EDTA at 
37° C (Life Technologies). Cells were stained with anti-
CD44 antibody (anti-CD44-FITC, clone G44–26, BD 
Biosciences) and anti-epithelial specific antigen (anti-
ESA-APC, clone HEA-125, Miltenyi Biotec) both at 
1:100 in PBS for 15 min in the dark. The DAPI nuclear 
dye (Sigma) was used at 200 ng/ml to exclude dead cells. 
For each flow cytometry assay, 100,000 cells were plated 
and 30,000 live cells counted on a Canto Cytometer (BD 
Biosciences) and analyzed using FACS Diva software 
(version 6.1.1, BD Biosciences). Using a FACSAria III 
(Becton Dickenson), cells were also fractionated (Biddle 
Figure 4: Changes in cell transitions, motility, and response to cisplatin induced by treatment. (A) Isolated populations 
of CD44high/ESAlow cells retain EMT characteristics 3 days after plating but treated with Cetuximab or Erlotinib begin to form clustered 
epithelial colonies (*). Three days after plating a mixture of EGFP+ EMT cells with unlabeled parental cells, EGFP+ cells retain their EMT-
like morphology but treatment with Cetuximab or Erlotinib induces transition into an epithelial phenotype (Scale = 25μm). (B–D). Images 
of scratches made in control and treated cultures showed reduced closure of scratches after treatment. (E) Cell counts after treatment 
with Cisplatin alone or combined with EGFR inhibition indicate more effective action of the combined drugs. (F) Cytometry assessing 
CD44 and ESA expression identifies 3 cell sub-populations in HNSCC cell lines. The majority cell population is ESAhigh and contains a 
CD44high/ ESAhigh epithelial stem cell population (A), and a CD44low differentiating non-stem cell population (B) (see Figure 2A). A third 
population (C) is CD44high/ESAlow and corresponds to cells that have undergone EMT. Three transitions occur – EMT, MET and transition 
into differentiation. Blocking the EGFR markedly enhanced the transitions indicated by red arrows.
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et al., 2011) as (a) CD44high/ESAlow cells (EMT-CSC 
phenotype), (b) the top 5% of CD44 expressing cells that 
also showed ESA expression (Epithelial CSC phenotype 
- EpiCSC), and (c) the 5% of cells with the lowest CD44 
expression also expressing ESA (differentiating cells). 
Proliferation assays
Total populations of the CA1 and Luc4 cell lines, 
together with their CD44high/ESAlow, CD44high/ESAhigh, 
and CD44low fractions were plated in triplicate at 1 × 103 
cells per well into 96-well plates. 24 hours later cells were 
treated with a range of concentrations of Cetuximab or 
Erlotinib for 1, 2 or 3 days. Cells were then fixed and 
stained with Cell Mask Deep Red and DAPI and assayed 
using the GE InCell 1000 imaging system. Based on the 
results of these assays, for subsequent experiments cells 
were exposed to Cetuximab at 100 µg/ml and at 500 ng/
ml. To assess effects on cell number of EGFR blocking 
in the presence of Cisplatin, cells were treated with 
Cetuximab or Erlotinib together with Cisplatin.
After 1, 2 and 3 days of treatment, 2-Deoxy-5-
Iodouridine (IdU) was added to the culture medium for 2 
hours at a final concentration of 50 µM to label cells in 
the S phase of the cell cycle. Cells were then washed in 
PBS before fixing with 4% paraformaldehyde for 15 min, 
re-washing and permeabilized with blocking solution (0.5% 
BSA, 0.2% Triton in PBS) for 30 min at room temperature. 
Cells were rewashed and incubated for 1 hour at RT 
with DNase (0.5 U/µl), 3 mM MgCl2 and anti-IdU/BrdU 
antibody (BD Address Cat# 347580) diluted to 100 µl/ml in 
blocking solution. After washing 3 times in PBS, cells were 
incubated in PBS containing an anti-mouse-488 secondary 
antibody (1:500) (Alexafluor, Life Tech), Cell Mask Deep 
Red and DAPI for 1 hour in the dark at RT. 
Apoptosis assays
Cell lines and sub-factions were treated with 
Cetuximab and Erlotinib before double staining with 
Annexin V-FITC and DAPI, or staining with anti-ESA-
APC (Miltenyi Biotec), anti-CD44-PE (BD Pharmingen), 
Annexin V-FITC (BD Pharmingen) and DAPI. Samples 
were examined on a Canto Cytometer (BD Bioscience) 
and analyzed with the FACS Diva version 6.1.1 (BD 
Biosciences) software. 
RNA extraction, cDNA synthesis and QPCR
RNA was extracted using the RNeasy® micro kit 
(Qiagen, Netherlands) followed by reverse transcription 
using the Superscript III first strand synthesis supermix 
(Invitrogen, USA). RT qPCR was performed in an ABI 
7500 real-time PCR system (Applied Biosystems, USA) 
using Power SYBR® green mix (Applied Biosystems, 
USA). QPCR cycling conditions were: 95°C for 10 mins, 
[95° C for 15 seconds, 60° C for 30 seconds, 72° C for 40 
seconds] (40 cycles), 95° C for 60 seconds, followed by 
dissociation curve analysis. Reverse transcribed Human 
Total Reference RNA (Stratagene) was used to generate 
a standard curve. Primer sequences were, designed using 
Primer-BLAST (NCBI).
Protein extraction and western blotting
Cells were grown to 70% confluence before being 
harvested and treated with 220 µl of pre-heated protein lysis 
buffer consisting of 1 mM Tris-Hcl, 10% (v/v) ammonium 
persulphate (APS), 0.5 M sodium orthovanadate (Sigma) 
at pH 8.4. Cells were removed and heated at 95° C for 2 
minutes. Protein was quantified (DC Protein Assay, Bio-
Rad) and 50 µl of 5x protein loading dye (Fisher Scientific) 
was added to the remaining 200 µl of sample. The primary 
antibodies with a standard western blotting technique were 
phospho-ERK (9106S, Cell Signaling), phospho-EGFR (04-
339, Millipore), PE-EGFR (555997, BD Biosciences) and 
β-Actin (sc47778, Santa Cruz). Secondary IgG-conjugated 
horse-radish peroxidase Abs (Dako) were followed by ECL 
detection (GE Healthcare).
Immunofluorescence
Cells were treated and fixed as above before 
being permeabilized with 0.1% Triton-X for 20 min, 
and then incubated with either Vimentin (DAKO 1:500) 
or E-Cadherin (Abcam 1:100). Wells were then washed 
3 times in PBS, before incubated in PBS containing an 
anti-mouse-488 secondary antibody (Alexafluor, Life Tech 
1:500), Cell Mask Deep Red at a 1:50,000 dilution (Life 
Technologies) and 1 µg/ml DAPI (Sigma). 
Labeling of cell transitions and cell motility
To examine directly the transitions occurring between 
cells of the EMT-CSC and the EPI-CSC compartments, cell 
lines were transduced with a constitutively expressed GFP 
plasmid. EMT-GFP and Epithelial Non-GFP cells were then 
sorted out from their parental populations and combined 
before replating and exposing to either Cetuximab or 
Erlotinib. Scratch assays were used to assess enhanced 
migration associated with a shift to EMT. Cells were plated 
for 24 hours, scratched, and then washed with PBS before 
replacing medium with or without the EGFR inhibitors. 
Cells were then imaged at 0, 16 and 24 hours and the degree 
of closure of the scratches analysed as outlined below.
Imaging and image analysis
Images were taken on an IN Cell 1000 Analyser (GE 
Healthcare) automated system. Images were processed and 




All assays were independently repeated a minimum 
of 3 times and significance of differences calculated using 
paired t-tests and indicated in the Figures as: P value 
<0.05 = *, <0.01 = ** or <0.001 = ***. Error bars represent 
the standard error of the mean (SEM).
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